US OptionsDetailed Quotes
BSX241004C89000
- 0.07
- 0.000.00%
15min DelayTrading Sep 23 09:45 ET
0.00High0.00Low
0.00Open0.07Pre Close0 Volume9 Open Interest89.00Strike Price0.00Turnover44.70%IV5.60%PremiumOct 4, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.0582Delta0.0409Gamma1205.00Leverage Ratio-0.0600Theta0.0003Rho70.13Eff Leverage0.0074Vega
Boston Scientific Stock Discussion
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...
Gapping up
$Enphase Energy (ENPH.US)$ 's stock went up by 2.3% after the company reported a better-than-expected operating profit for the second quarter, buoyed by renewed demand in the U.S. market.
$Texas Instruments (TXN.US)$ stock increased by 1.7% as the semiconductor company reported stronger-than-expected earnings for the second quarter, with adjusted earnings per share that exceeded estimates.
$AT&T (T.US)$ ...
Investors have largely priced in the chances of the Federal Reserve cutting interest rates at its September meeting. Combined with rising confidence in a soft landing, the market has continued its rally, with rate-sensitive sectors such as small caps and industrials rising in recent weeks. $Russell 2000 Index (.RUT.US)$
...
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
$Tesla (TSLA.US)$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
No comment yet